Perlmutter Cancer Center at NYU Langone | Strategic Alliance Partners

Latest from Perlmutter Cancer Center at NYU Langone


Hematologic Malignancies: Chaired by Marc Braunstein, MD, PhD

December 14, 2020

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of hematologic malignancies.

Adjuvant Nivolumab Displays Survival Benefits in High-Risk Resected Melanoma

December 04, 2020

December 4, 2020 — Adjuvant nivolumab demonstrated clinically meaningful improvements in relapse-free survival, overall survival, and distant metastasis-free survival vs placebo in patients with high-risk resected melanoma, even after accounting for disease stage and post-recurrence survival, supporting the use of the anti–PD-1 antibody as a standard adjuvant therapy.

Dr. Weber on the Treatment of LDH-High Melanoma

December 01, 2020

Jeffrey S. Weber, MD, PhD, ​deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses the treatment of lactate dehydrogenase (LDH)​–high melanoma.

x